{"id":61475,"date":"2025-06-24T04:04:25","date_gmt":"2025-06-24T02:04:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/"},"modified":"2025-06-24T04:04:25","modified_gmt":"2025-06-24T02:04:25","slug":"arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/","title":{"rendered":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair"},"content":{"rendered":"
\n

PRINCETON, N.J.–(BUSINESS WIRE)–ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor\u2019easter Ventures, and new investor AB Magnitude.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath,\u201d said Kevin Krause, President and CEO. \u201cThis raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria.\u201d<\/p>\n

\nFollowing the closing of this financing, ArrePath concluded a search for a new Chair of the Board of Directors with the appointment of Diego Miralles, M.D. Dr. Miralles comes to ArrePath with extensive experience in the biotech and pharmaceutical industry in many strategic, development and leadership roles. He was recently nominated to the Board of Directors of Contineum (NASDAQ: CTNM) and serves on the Board of Artiva (NASDAQ: ARTV). Dr. Miralles, an Infectious Diseases trained clinician and scientist, has extensive executive experience including as CEO of AZURNA Therapeutics, Inc., Laronde, Inc., and Vividion Therapeutics, Inc, and President of Adaptive Therapeutics. Previous to these roles, Dr. Miralles held various senior executive and R&D leadership positions at Johnson & Johnson.<\/p>\n

\nDr. Miralles received his M.D. degree from the University of Buenos Aires, completed his residency in Internal Medicine at the Mayo Clinic and a fellowship in Infectious Diseases at The New York Hospital\/Cornell University and was on the faculty at Duke University.<\/p>\n

\n\u201cWe are excited to welcome Dr. Miralles to the ArrePath Board of Directors,\u201d said Kevin Krause. \u201cHis decades of experience as an executive and board member in both private and public companies, along with his proven experience scaling emerging biotech companies, will provide invaluable insights and experience as we approach several near-term inflection points for ArrePath. I look forward to working with him as the company evolves into the next phase of growth.\u201d<\/p>\n

\n\u201cI am really excited to join Kevin Krause, our outstanding newly appointed CEO, and the Board at ArrePath,\u201d said Diego Miralles. \u201cThe company\u2019s AI discovery platform which, coupled with the team\u2019s deep experience in antimicrobial development, will enable us to bring forward superior products to address unmet needs in antimicrobials. Recent approvals in antimicrobials demonstrate the continued need for improved products, a space where ArrePath will become a leader.\u201d<\/p>\n

\nAbout ArrePath<\/b><\/p>\n

\nArrePath combines the power of human intelligence with AI\/ML to address the challenge of efficient drug discovery, which is a complex optimization process paired with an unimaginable number of chemical possibilities. Our AI\/ML platform couples virtual and experimental compound design and testing to create efficiency at identifying novel compounds that are both active and have the attributes required to progress. To date, we have identified antibiotic hits active against three clinically novel targets. Of these, we are progressing AP-001 to focus on the large outpatient UTI market and a hospital avoidance strategy plus the potential for step-down from hospital-based IV therapies. We also have discovered multiple novel compound families active against non-tuberculous Mycobacteria (NTM). For more information on ArrePath\u2019s innovative work and mission, please visit http:\/\/www.arrepath.com\/<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nArrePath<\/b>
Reena Pagnoni
\n
reena.pagnoni@arrepath.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PRINCETON, N.J.–(BUSINESS WIRE)–ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61475","6":"format-standard","7":"category-industry"},"yoast_head":"\nArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J.–(BUSINESS WIRE)–ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T02:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair\",\"datePublished\":\"2025-06-24T02:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/\"},\"wordCount\":630,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623250740\\\/en\\\/2504834\\\/22\\\/ArrePath_logo_rbg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/\",\"name\":\"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623250740\\\/en\\\/2504834\\\/22\\\/ArrePath_logo_rbg.jpg\",\"datePublished\":\"2025-06-24T02:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623250740\\\/en\\\/2504834\\\/22\\\/ArrePath_logo_rbg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623250740\\\/en\\\/2504834\\\/22\\\/ArrePath_logo_rbg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/","og_locale":"en_US","og_type":"article","og_title":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend","og_description":"PRINCETON, N.J.–(BUSINESS WIRE)–ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-24T02:04:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair","datePublished":"2025-06-24T02:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/"},"wordCount":630,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/","url":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/","name":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg","datePublished":"2025-06-24T02:04:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250623250740\/en\/2504834\/22\/ArrePath_logo_rbg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/arrepath-announces-closing-of-their-next-financing-round-and-appointment-of-a-new-board-chair\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61475"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61475\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}